Metch develops the world's first targeted antibacterial products, set to replace antibiotics. The company is viewed as global leader spearheading this exciting new field. With Metch endolysin technology, for the first time we can kill only the unwanted bacteria - including antibiotic resistant strains - while preserving the beneficial bacteria, essential for our health. In addition, scientists do not expect emergence of resistance against endolysins, based on their working mechanism. This unlocks a completely new approach in dealing with the bacteria around us - also enabling preventive daily therapy against only unwanted bacteria for as long as needed.
